Drug Discovery World

NOVEMBER 7, 2022

CELMoDs are designed to attack cancer by binding to a regulatory protein called cereblon, which then triggers the degradation of key cancer-driving proteins. . Scientists have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. .

Scientist 52

Scientist Drugs Protein Research 52

pharmaphorum

JANUARY 18, 2022

Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1. To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.

Protein 52

Protein Genome Genomics Research 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

JUNE 8, 2021

SMA is caused by mutations in the survival motor neuron 1 ( SMN1) gene, which along with the SMN2 gene, encode the SMN protein. It is administered as a one-time IV administration and expression of the SMN protein from the gene improves muscle movement and function, and ultimately survival. With a price tag of over $2.5

Gene Therapy 110

Gene Therapy Gene Protein Trials 110

Delveinsight

FEBRUARY 9, 2021

The move came not long after healthcare investor giant Deerfield Management has forged a partnership to create the Center for Protein Degradation, investing worth USD 80 million. As per the company, their one-time CAR-T cell therapy will be crucial in clinical practice in relapsed or refractory large B-cell lymphoma cases.

FDA Approval 52

FDA Approval Marketing Research Protein 52